These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 1347112)
21. Ondansetron versus dolasetron: a comparison study in the prevention of postoperative nausea and vomiting in patients undergoing gynecological procedures. Browning BA; Fort CA; Kemp KD; Shimata MF; Strube MD AANA J; 2004 Apr; 72(2):129-32. PubMed ID: 15098526 [TBL] [Abstract][Full Text] [Related]
22. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Lordick F; Ehlken B; Ihbe-Heffinger A; Berger K; Krobot KJ; Pellissier J; Davies G; Deuson R Eur J Cancer; 2007 Jan; 43(2):299-307. PubMed ID: 17134890 [TBL] [Abstract][Full Text] [Related]
23. The use of oral granisetron versus intravenous ondansetron for antiemetic prophylaxis in patients undergoing laparoscopic surgery: the effect on emetic symptoms and quality of recovery. White PF; Tang J; Hamza MA; Ogunnaike B; Lo M; Wender RH; Naruse R; Sloninsky A; Kariger R; Cunneen S; Khalili T Anesth Analg; 2006 May; 102(5):1387-93. PubMed ID: 16632815 [TBL] [Abstract][Full Text] [Related]
24. A prospective survey of knowledge and perceptions of ondansetron: what do health care workers know about this drug? Marra C; Nimmo CR; Jewesson P Can J Hosp Pharm; 1995 Dec; 48(6):336-42. PubMed ID: 10153865 [TBL] [Abstract][Full Text] [Related]
25. Compliance with guidelines results in appropriate ondansetron prescribing at Christchurch Hospital. Busch AF; Pearce MJ; Allen B; Begg EJ N Z Med J; 1996 Apr; 109(1020):142-4. PubMed ID: 8649670 [TBL] [Abstract][Full Text] [Related]
26. Pharmaceutical development of ondansetron tablets. Leak RE; Woodford JD Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S63-6. PubMed ID: 2533901 [TBL] [Abstract][Full Text] [Related]
27. Ondansetron to prevent chemotherapy-induced vomiting. Drug Ther Bull; 1992 Mar; 30(6):21-3. PubMed ID: 1534293 [No Abstract] [Full Text] [Related]
28. Using ondansetron with pediatric patients undergoing total body irradiation. Witherow P; Wilson K Oncol Nurs Forum; 1991; 18(8):1416-7. PubMed ID: 1837082 [No Abstract] [Full Text] [Related]
29. Pharmacological and anti-emetic properties of ondansetron. Tyers MB; Bunce KT; Humphrey PP Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S15-9. PubMed ID: 2533894 [TBL] [Abstract][Full Text] [Related]
31. Ondansetron: a new entity in emesis control. Graves T DICP; 1990 Nov; 24(11 Suppl):S51-4. PubMed ID: 2148659 [TBL] [Abstract][Full Text] [Related]
32. Clinical and economic impact of oral ondansetron for vomiting in a pediatric emergency department. Hervás D; Armero C; Carrión T; Utrera JF; Hervás JA Pediatr Emerg Care; 2012 Nov; 28(11):1166-8. PubMed ID: 23114242 [TBL] [Abstract][Full Text] [Related]
33. Balancing efficacy with cost: antiemetic control in the pediatric stem cell transplant (SCT) population. Parsons SK; Hoorntje LE; Levine KJ; Mayer DK; Eichelberger WJ; Guinan EC Bone Marrow Transplant; 2000 Mar; 25(5):553-7. PubMed ID: 10713635 [TBL] [Abstract][Full Text] [Related]
34. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. Schmoll HJ Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897 [TBL] [Abstract][Full Text] [Related]
35. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. Plosker GL; Milne RJ Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044 [TBL] [Abstract][Full Text] [Related]